605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I

Protein degradation of MYC GSPT1 is a novel treatment modality for aggressive T cell acute lymphoblastic leukemias

Immunotherapy resistant ALL cells exhibit selective dependence on glutamine and specific transporters for growth and survival

Vitamin K3 metabolic fate determines pro survival or ferroptotic outcomes in multiple myeloma via UBIAD1 and reductase axis

Results of the Phase II d PRISM study Daratumumab in high risk MGUS and low risk smoldering myeloma

Targeting BTKi resistant CLL using the dual irreversible reversible 4th generation BTK inhibitor rocbrutinib

Biphasic effects of cyclophosphamide on l asparaginase hypersensitivity and resistance in mice

The efficacy of Obinutuzumab zanubrutinib combined with pomalidomide and Venetoclax for the treatment of high risk mutated Mantle Cell Lymphoma MCL A prospective  open label  single arm study

PRMT5 is a therapeutic vulnerability in cutaneous T cell lymphoma

Embryonic ectoderm development EED inhibitor APG 5918 overcomes immunomodulatory drug IMiD resistance as monotherapy and synergizes with IMiDs cereblon E3 ligase modulators CELMoDs in preclinical models of multiple myeloma MM

A combination strategy of inotuzumab ozogamicin InO and BCL 2 family inhibitors prevents the emergence of PGP ino resistant MRD in B cell acute lymphoblastic leukemia

Selenocysteine dependency renders central nervous system leukaemia therapeutically sensitive to ferroptosis

CD47 blockade induces programmed necroptosis and complements the effects of BCL 2 inhibition in lymphoid malignancies

Repurposing of disulfiram as a novel therapeutic agent to treat crebbp mutant diffuse large B cell lymphoma DLBCL

Dioscin suppresses the progression of diffuse large B cell lymphoma by modulating acaca dependent histone H3K27 acetylation and inducing mitophagy

IRF4 maintenance in multiple myeloma is conserved in de novo derived inobrodib resistance conferring cross resistance to immunomodulatory drugs

Next generation tumor specific anti CD30 ADC as a new therapy in hemato oncology